AU2011331232B2 - Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) - Google Patents

Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) Download PDF

Info

Publication number
AU2011331232B2
AU2011331232B2 AU2011331232A AU2011331232A AU2011331232B2 AU 2011331232 B2 AU2011331232 B2 AU 2011331232B2 AU 2011331232 A AU2011331232 A AU 2011331232A AU 2011331232 A AU2011331232 A AU 2011331232A AU 2011331232 B2 AU2011331232 B2 AU 2011331232B2
Authority
AU
Australia
Prior art keywords
arg
mutein
tyr
ser
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011331232A
Other languages
English (en)
Other versions
AU2011331232A1 (en
Inventor
Gabriele Matschiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
Original Assignee
Pieris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris AG filed Critical Pieris AG
Publication of AU2011331232A1 publication Critical patent/AU2011331232A1/en
Application granted granted Critical
Publication of AU2011331232B2 publication Critical patent/AU2011331232B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011331232A 2010-11-15 2011-11-15 Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) Ceased AU2011331232B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41370610P 2010-11-15 2010-11-15
EP10191228.5 2010-11-15
EP10191228 2010-11-15
US61/413,706 2010-11-15
PCT/EP2011/070119 WO2012065978A1 (en) 2010-11-15 2011-11-15 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Publications (2)

Publication Number Publication Date
AU2011331232A1 AU2011331232A1 (en) 2013-05-23
AU2011331232B2 true AU2011331232B2 (en) 2015-05-07

Family

ID=45346426

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011331232A Ceased AU2011331232B2 (en) 2010-11-15 2011-11-15 Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)

Country Status (7)

Country Link
US (1) US9260492B2 (cg-RX-API-DMAC7.html)
EP (1) EP2640740B1 (cg-RX-API-DMAC7.html)
JP (1) JP6100694B2 (cg-RX-API-DMAC7.html)
AU (1) AU2011331232B2 (cg-RX-API-DMAC7.html)
CA (1) CA2817779C (cg-RX-API-DMAC7.html)
DK (1) DK2640740T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012065978A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2564125C2 (ru) 2009-12-07 2015-09-27 Пирис Аг Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
SG10201912019WA (en) * 2014-05-22 2020-02-27 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
US11382963B2 (en) * 2015-01-12 2022-07-12 Pieris Pharmaceuticals Gmbh Engineered T cells and uses therefor
CA2973640A1 (en) 2015-01-28 2016-08-04 Rachida Siham Bel Aiba Novel proteins specific for angiogenesis
BR112017020434A2 (pt) 2015-05-04 2018-06-26 Pieris Pharmaceuticals Gmbh polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
MX390894B (es) 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
KR20180008649A (ko) * 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인
EP3115066A1 (en) * 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
KR102818445B1 (ko) * 2015-09-23 2025-06-10 브리스톨-마이어스 스큅 컴퍼니 글리피칸-3-결합 피브로넥틴 기반 스캐폴드 분자
EA035586B1 (ru) 2015-11-30 2020-07-10 Пиерис Острелиа Пти Лтд. Новые антиангиогенные слитые белки
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
EP3503930B1 (en) 2016-08-29 2024-12-11 Fred Hutchinson Cancer Center Chelating platform for delivery of radionuclides
CN111542535A (zh) 2017-12-20 2020-08-14 圣安娜儿童癌症研究中心 配体调控的蛋白-蛋白相互作用系统
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
CA3127973A1 (en) * 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
AU2021285201A1 (en) 2020-06-05 2022-11-24 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1BB

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
KR20010052622A (ko) 1998-06-08 2001-06-25 프리돌린 클라우스너, 롤란드 비. 보레르 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2002024866A2 (en) * 2000-09-21 2002-03-28 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
WO2009012394A1 (en) 2007-07-17 2009-01-22 Medarex, Inc. Monoclonal antibodies against glypican-3
US8420051B2 (en) * 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Akutsu N. et al. "Association of glypican-3 expression with growth signalling molecules in hepatocellular carcinoma" World J. Gastroenterol. (2010) 16 (28): 3521-3528 *
Capurro M. I. et al. "Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling" Cancer Res. (2005) 65 (14): 6245-6254 *
Cheng W. et al. "Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling Pathway" Carcinogenesis (2008) 29 (7): 1319-1326 *
Jakubovic B. D. and Jothy S. "Glypican-3: From the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma" Experimental and Molecular Pathology (2007) 82 (2): 184-189 *
Kwack M. H. et al. "Cellular Changes Resulting from Forced Expression of Glypican-3 in Hepatocellular Carcinoma Cells" Mol. Cells (2006) 21 (2): 224-228 *
Liu H. et al. "Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma" World J. Gastroenterol. (2010) 16 (35): 4410-4415 *
Nakatsura T. and Nishimura Y. "Usefulness of the Novel Oncofetal Antigen Glypican-3 for Diagnosis of Hepatocellular Carcinoma and Melanoma" BioDrugs (2005) 19 (2): 71-77 *
Skerra A. "Alternative binding proteins: Anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities" FEBS Journal (2008) 275 (11): 2677-2683 *
Zhu Z.-W. et al. "Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders" Gut (2001) 48: 558-564 *

Also Published As

Publication number Publication date
WO2012065978A1 (en) 2012-05-24
JP2014502149A (ja) 2014-01-30
CA2817779A1 (en) 2012-05-24
AU2011331232A1 (en) 2013-05-23
CA2817779C (en) 2019-02-19
DK2640740T3 (en) 2017-06-26
EP2640740B1 (en) 2017-03-15
US20130296258A1 (en) 2013-11-07
US9260492B2 (en) 2016-02-16
JP6100694B2 (ja) 2017-03-22
EP2640740A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
AU2011331232B2 (en) Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
AU2011290751B2 (en) Binding proteins for Hepcidin
JP7217783B2 (ja) グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン
US9221885B2 (en) Muteins of human lipocalin 2 with affinity for CTLA-4
EP2245054B1 (en) Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same
AU2010329995A1 (en) Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired